CYTOSORBENTS CORP (CTSO) Stock Overview
NASDAQ:CTSO - US23283X2062 - Common Stock
CTSO Key Statistics, Chart & Performance
The current stock price of CTSO is 0.9434 USD. In the past month the price increased by 8.54%. In the past year, price decreased by -10.15%.
CTSO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.07 | 230.89B | ||
| ISRG | INTUITIVE SURGICAL INC | 58.79 | 169.67B | ||
| BSX | BOSTON SCIENTIFIC CORP | 37.28 | 156.32B | ||
| SYK | STRYKER CORP | 30.46 | 149.64B | ||
| MDT | MEDTRONIC PLC | 16.78 | 119.05B | ||
| BDX | BECTON DICKINSON AND CO | 13.52 | 55.31B | ||
| IDXX | IDEXX LABORATORIES INC | 53.88 | 51.77B | ||
| EW | EDWARDS LIFESCIENCES CORP | 31.65 | 47.75B | ||
| RMD | RESMED INC | 28.74 | 40.19B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.82 | 33.66B | ||
| DXCM | DEXCOM INC | 44.32 | 29.55B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.42 | 26.56B |
Related stock screener links
About CTSO
Company Profile
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 149 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Company Info
CYTOSORBENTS CORP
305 College Road East
Princeton NEW JERSEY 08852 US
CEO: Phillip P. Chan
Employees: 149
Phone: 19733298885
CYTOSORBENTS CORP / CTSO FAQ
What is the stock price of CYTOSORBENTS CORP today?
The current stock price of CTSO is 0.9434 USD. The price increased by 0.84% in the last trading session.
What is the ticker symbol for CYTOSORBENTS CORP stock?
The exchange symbol of CYTOSORBENTS CORP is CTSO and it is listed on the Nasdaq exchange.
On which exchange is CTSO stock listed?
CTSO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTOSORBENTS CORP stock?
8 analysts have analysed CTSO and the average price target is 5.1 USD. This implies a price increase of 440.6% is expected in the next year compared to the current price of 0.9434. Check the CYTOSORBENTS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTOSORBENTS CORP worth?
CYTOSORBENTS CORP (CTSO) has a market capitalization of 59.21M USD. This makes CTSO a Micro Cap stock.
How many employees does CYTOSORBENTS CORP have?
CYTOSORBENTS CORP (CTSO) currently has 149 employees.
What are the support and resistance levels for CYTOSORBENTS CORP (CTSO) stock?
CYTOSORBENTS CORP (CTSO) has a support level at 0.88 and a resistance level at 0.95. Check the full technical report for a detailed analysis of CTSO support and resistance levels.
Is CYTOSORBENTS CORP (CTSO) expected to grow?
The Revenue of CYTOSORBENTS CORP (CTSO) is expected to grow by 0.37% in the next year. Check the estimates tab for more information on the CTSO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYTOSORBENTS CORP (CTSO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTSO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTSO, evaluating the profitability, health, valuation and growth aspects
- CYTOSORBENTS CORP (CTSO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTOSORBENTS CORP (CTSO) Sales and EPS estimates to see what analysts future expectations are.
- CYTOSORBENTS CORP (CTSO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTOSORBENTS CORP (CTSO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTOSORBENTS CORP (CTSO) Stock Chart to make your own analysis
- CYTOSORBENTS CORP (CTSO) Latest news and press-releases to stay up to date.
Does CYTOSORBENTS CORP (CTSO) stock pay dividends?
CTSO does not pay a dividend.
When does CYTOSORBENTS CORP (CTSO) report earnings?
CYTOSORBENTS CORP (CTSO) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of CYTOSORBENTS CORP (CTSO)?
CYTOSORBENTS CORP (CTSO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is the Short Interest ratio of CYTOSORBENTS CORP (CTSO) stock?
The outstanding short interest for CYTOSORBENTS CORP (CTSO) is 2.58% of its float. Check the ownership tab for more information on the CTSO short interest.
CTSO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CTSO. When comparing the yearly performance of all stocks, CTSO is a bad performer in the overall market: 61.02% of all stocks are doing better.
CTSO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CTSO. CTSO may be in some trouble as it scores bad on both profitability and health.
CTSO Financial Highlights
Over the last trailing twelve months CTSO reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 68.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.32% | ||
| ROE | -84.15% | ||
| Debt/Equity | 1.24 |
CTSO Forecast & Estimates
8 analysts have analysed CTSO and the average price target is 5.1 USD. This implies a price increase of 440.6% is expected in the next year compared to the current price of 0.9434.
For the next year, analysts expect an EPS growth of 65.11% and a revenue growth 0.37% for CTSO